A novel therapy for melanoma developed in mice: transformation of melanoma into dendritic cells with Listeria monocytogenes

Lucia Bronchalo-Vicente, Estela Rodriguez-Del Rio, Javier Freire, Ricardo Calderon-Gonzalez, Elisabet Frande-Cabanes, Jose Javier Gomez-Roman, Hector Fernandez-Llaca, Sonsoles Yañez-Diaz, Carmen Alvarez-Dominguez

Research output: Contribution to journalArticlepeer-review

15 Citations (Scopus)

Abstract

Listeria monocytogenes is a gram-positive bacteria and human pathogen widely used in cancer immunotherapy because of its capacity to induce a specific cytotoxic T cell response in tumours. This bacterial pathogen strongly induces innate and specific immunity with the potential to overcome tumour induced tolerance and weak immunogenicity. Here, we propose a Listeria based vaccination for melanoma based in its tropism for these tumour cells and its ability to transform in vitro and in vivo melanoma cells into matured and activated dendritic cells with competent microbicidal and antigen processing abilities. This Listeria based vaccination using low doses of the pathogen caused melanoma regression by apoptosis as well as bacterial clearance. Vaccination efficacy is LLO dependent and implies the reduction of LLO-specific CD4+ T cell responses, strong stimulation of innate pro-inflammatory immune cells and a prevalence of LLO-specific CD8+ T cells involved in tumour regression and Listeria elimination. These results support the use of low doses of pathogenic Listeria as safe melanoma therapeutic vaccines that do not require antibiotics for bacterial removal.
Original languageEnglish
Article numbere0117923
Number of pages18
JournalPLoS ONE
Volume10
Issue number3
DOIs
Publication statusPublished - 11 Mar 2015
Externally publishedYes

Fingerprint

Dive into the research topics of 'A novel therapy for melanoma developed in mice: transformation of melanoma into dendritic cells with Listeria monocytogenes'. Together they form a unique fingerprint.

Cite this